JAG1 / JAGL1 / CD339 Protein (His Tag)

Protein Jagged-1 ( JAG1 / JAGL1 / CD339 ) Protein

JAG1 / JAGL1 / CD339 Protein Product Information

• Synonym: JAG1, AGS, AHD, AWS, CD339, HJ1, JAGL1, MGC104644
• Protein Construction: A DNA sequence encoding the human JAG1 ( NP_000205.1 ) extracellular domain ( Met 1 - Ser 1046 ) was expressed, fused with a polyhistidine tag at the C-terminus
• Source: Human
• Expression Host: Human Cells

JAG1 / JAGL1 / CD339 Protein QC Testing

• Purity: > 85 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Gln 34
• Molecular Mass: The recombinant human JAG1 consists of 1024 amino acids and has a predicted molecular mass of 112 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh JAG1 is approximately 160-180 kDa due to glycosylation
• Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: JAG1 protein

JAG1 / JAGL1 / CD339 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

JAG1 / JAGL1 / CD339 Protein Description

Protein jagged-1, also known as JAG1, JAGL1 and CD339, is a single-pass type I  membrane protein which contains 1 DSL domain and 15 EGF-like domains. JAG1 is widely expressed in adult and fetal tissues. The expression of JAG1 is up-regulated in cervical squamous cell carcinoma. JAG1 is also expressed in bone marrow cell line HS-27a which supports the long-term maintenance of immature progenitor cells. JAG1 is a ligand for multiple Notch receptors. It is involved in the mediation of Notch signaling. JAG1 may be involved in cell-fate decisions during hematopoiesis. JAG1 seems to be involved in early and late stages of mammalian cardiovascular development.

JAG1 inhibits myoblast differentiation and enhances fibroblast growth factor-induced angiogenesis. Defects in JAG1 are the cause of Alagille syndrome type 1 (ALGS1). Alagille syndrome is an autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. Defects in JAG1 are also a cause of tetralogy of Fallot (TOF). TOF is a congenital heart anomaly which consists of pulmonary stenosis, ventricular septal defect, dextroposition of the aorta (aorta is on the right side instead of the left) and hypertrophy of the right ventricle. This condition results in a blue baby at birth due to inadequate oxygenation.

References

1. Oda T.et al., 1997, Nat. Genet. 16:235-242.
2. Krantz I.D. et al., 1998, Am. J. Hum. Genet. 62:1361-1369.
3. Li L. et al., 1998, Immunity. 8:43-55.
4. Jones E.A. et al., 2000, J. Med. Genet. 37: 658-662.
5. Roepke A.et al., 2003, Hum. Mutat. 21:100-100.
6. Jurkiewicz D.et al., 2005, Hum. Mutat. 25:321-321.
7. Warthen D.M.et al., 2006, Hum. Mutat. 27:436-443.